Design of intranasal dosage forms: biopharmaceutical aspects


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper provides an analysis and comparative characteristics of the types of dosage forms of registered intranasal drugs. By using the biopharmaceutical features of the intranasal route of administration, the investigators show the advantages and disadvantages of traditional dosage forms, such as solutions, ointments, lyophilisates, and sprays) and the promising nature of mucoadhesive thermoreversive gels. The current matrix-forming agents (smart polymers and high-molecular-weight compounds) are considered to be promising for designing intranasal gels.

Full Text

Restricted Access

About the authors

Natalya Borisovna Demina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: nbd217@mail.ru
professor at the Department of pharmaceutical technology Institute of Pharmacy

Elena Olegovna Bakhrushina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: bachrauschenh@mail.ru
Associate Professor at the Department of pharmaceutical technology Institute of Pharmacy

Aleksandr Ivanovich Bardakov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: bardakovai@rambler.ru
Associate Professorat the Department of pharmaceutical technology Institute of Pharmacy

Ivan Ivanovich Krasnyuk

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: krasnyuki@mail.ru
head of Department of pharmaceutical technology Institute of Pharmacy

References

  1. Государственный реестр лекарственных средств.
  2. Денисов Л.А., Шолохов И.В. Открытие интерферона и его клиническое применение. Инфекционные болезни: новости, мнения, обучение, 2017; 1: 23-31.
  3. Lindemann J., Leiacker R., Rettinger G., Keck T. Nasal mucosal temperature during respiration. Clin. Otolaryngol. Allied. Sci., 2002 Jun; 27 (3): 135-9.
  4. Ugwoke M.I., Agu R.U., Verbeke N., Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev., 2005 Nov 3; 57 (11): 1640-65.
  5. Farina D. Regulatory aspects of nasaland pulmonary spray drug products, published in Handbook of non-invasive drug delivery systems. (ed. V. Kulkarni). Elsevier, Oxford, UK; 2010: 24790.
  6. Бариев Э.А., Бардаков А.И., Ляпунов Н.А., Краснюк И.И. Обоснование выбора не инъекционного пути введения налоксона. Вестник Воронежского государственного университета. Серия: Химия, Биология, Фармация, 2017; 1: 133-7.
  7. Абрамова С. Принципы выбора назальных деконгестантов. Фармацевтический вестник, 2015; 27.
  8. Харенко Е.А., Ларионова Н.И., Демина Н.Б. Мукоадгезивные лекарственные формы. Химикофармацевтический журнал. 2009; 4 (43): 21-9.
  9. Nakamura F., Ohta R., Machida Y., Nagai T. In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int.J.Pharm., 1996; 134: 173-81.
  10. Chonkar A., Nayak U., Udupa N. Smart Polymers in Nasal Drug Delivery. Indian J. Pharm. Sci., 2015; 77 (4): 367-75.
  11. Pund S., Rasve G., Borade G. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur.J.Pharm. Sci., 2013; 48: 195-201.
  12. Anurova M.N., Bakhrushina E.O., Demina N.B. Review of Contemporary Gel-Forming Agents in the Technology of Dosage Forms. Pharmaceutical Chemistry Journal, 2015; 49, (9): 627-34. https://doi.org/10.1007/s11094-015-1342-5
  13. Bansal V., Sharma P.K., Sharma N., Pal O.P., Malviya R. Applications of chitosan and chitosan derivatives in drug delivery. Advances in Biological Research., 2011; 1 (5): 28-37.
  14. Krauland A.H., Leitner V.M., Bernkop-Schnurch A. Improvement in the in situ gelling properties of deacetylatedgel-lan gum by the immobilization of thiol groups. J. Pharm. Sci., 2003; 92: 1234-41.
  15. Харькова Н.А. Эффективность применения гидрогелевых материалов «Колегель-АДЛ» и электрофореза в лечении обструктивной патологии придаточных пазух носа. Физиотерапия, бальнеология и реабилитация,2015; 4: 33-8.
  16. Illum L. Nasal drug delivery - Recent developments and future prospects. J. Control. Release., 2012; 161: 254-63.
  17. Bhalerao A.V., Lonkar S.L., Deshkar S.S., Shirolkar S.V., Deshpande A.D. Nasal mucoadhesive in situ gel of ondransetron hydrochloride. Indian J. Pharm. Sci., 2009; 71: 711-3.
  18. Mura P., Mennini N., Nativi C., Richichi B. In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin. Eur. J. Pharm. Biopharm., 2018 Jan; 122: 54-61. https://doi.org/10.1016/j. ejpb.2017.10.008
  19. Pandey P., Cabot P.J., Wallwork B., Panizza B.J., Parekh H.S. Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - A platform for therapeutic delivery to mucosal sinus tissue. Eur. J. Pharm. Sci., 2017 Jan 1; 96: 499-507. https://doi.org/10.1016/j. ejps.2016.10.017
  20. Li C., Li C., Liu Z., Li Q., Yan X., Liu Y., Lu W. Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carra-geenan. Int. J. Pharm., 2014 Oct 20; 474 (1-2): 123-33. https:// doi.org/10.1016/j.ijpharm.2014.08.023

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies